Details of the Drug

General Information of Drug (ID: DMOAET3)

• Drug Name: Autologous T-cell therapy
• Synonyms: Anti-PSMA designer T cells, Roger Williams; Gene therapy (chimeric anti-PSMA antibody-TCR), Roger Williams; Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer); Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center; Retrovirus-based ex vivo gene therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

• Drug Type: Antibody
• Cross-matching ID: TTD ID: D04UWG

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate carboxypeptidase II (GCPII)	TT9G4N0	FOLH1_HUMAN	Not Available	[2]
T-cell surface glycoprotein CD3 epsilon (CD3E)	TTZAT79	CD3E_HUMAN	Not Available	[2]
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Not Available	[2]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 02 Neoplasm
• Disease Class: ICD-11: 2C82 Prostate cancer
• The Studied Tissue: Prostate
• The Studied Disease: Prostate cancer [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
T-cell surface glycoprotein CD3 epsilon (CD3E)	DTT	CD3E	1.53E-06	-0.93	-1.37
Glutamate carboxypeptidase II (GCPII)	DTT	FOLH1	1.40E-09	2.08	2.21

References

• [1] Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 2014 May 16;3(5):e16.
• [2] Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.